Protagonist Announces Appointment of Arturo Molina, M.D., M.S., F.A.C.P. as Chief Medical Officer

Accomplished hematologist-oncologist will provide medical, clinical development, and strategic operational leadership to the ongoing rusfertide Phase 3 development program NEWARK, Calif., Nov. 2, 2022 /PRNewswire/ -- Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company")...

Click to view original post